| Name | Title | Contact Details |
|---|---|---|
Bryan Tweed |
Senior Vice President, Sales and Key Accounts - North America | Profile |
Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.
Targanta Therapeutics Corp. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We were founded in 2006 as GO3ETA, Inc., but do business as the Global Organization for EPA and DHA Omega-3s (GOED). The roots of GOED go back to 2000 when the industry collaborated to petition the US Food and Drug Administration to establish a heart disease risk reduction claim for omega-3s. The companies involved later formalized the relationship by forming the Omega-3 Working Group at the Council for Responsible Nutrition and collaborating again to develop what is now known as the GOED Voluntary Monograph. In 2006, when the Working Group was dissolved, twelve of the companies banded together to found GOED with a strong mandate to grow our membership to represent all sections of the EPA and DHA market.
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasĪ¦, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.